Romosozumab-Aqqg

Common brands: Evenity, Prolia, Vitamin D, 7030 Calcium Gold, 7030 Calcium Premium

Top reporter: Amgen, Inc

RANK Ligand Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Provitamin D2 Compound [EPC]Calcium [EPC]Corticosteroid [EPC]
12,630
Total Reports
10,013
Serious Reports
678
Death Reports
30
Reported Reactions
Death Report Ratio: High (5.37%)

Patient Demographics

Male
680
Female
9,005

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Romosozumab-Aqqg.

# Reaction Reports % of Total
1 FALL 729
7.9%
2 FRACTURE 645
7.0%
3 ARTHRALGIA 579
6.3%
4 INJECTION SITE PAIN 536
5.8%
5 OFF LABEL USE 476
5.1%
6 BONE DENSITY ABNORMAL 461
5.0%
7 HOSPITALISATION 437
4.7%
8 HEADACHE 421
4.5%
9 PRODUCT STORAGE ERROR 353
3.8%
10 PAIN IN EXTREMITY 286
3.1%
11 SPINAL FRACTURE 283
3.1%
12 DEATH 281
3.0%
13 INJECTION SITE SWELLING 280
3.0%
14 PAIN 274
3.0%
15 FEMUR FRACTURE 270
2.9%
16 INJECTION SITE ERYTHEMA 268
2.9%
17 FATIGUE 255
2.8%
18 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 224
2.4%
19 DIZZINESS 221
2.4%
20 BONE PAIN 207
2.2%
21 CARDIAC FAILURE 201
2.2%
22 RASH 190
2.1%
23 BACK PAIN 189
2.0%
24 NAUSEA 189
2.0%
25 MYALGIA 185
2.0%
26 MYOCARDIAL INFARCTION 168
1.8%
27 SPINAL COMPRESSION FRACTURE 166
1.8%
28 DRUG INEFFECTIVE 164
1.8%
29 BONE DENSITY DECREASED 162
1.7%
30 PNEUMONIA 161
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.